Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab

Journal of the American Academy of Dermatology

Volumn 46, Issue 6, 2002, Pages 886-891

  Schopf, Rudolf E ^a   Aust, Holger ^a   Knop, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACANTHOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PRURITUS; PSORIASIS; SKIN BIOPSY;

EID: 0036621139     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120472     Document Type: Article

References (22)

1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-5.
2. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829-30.
3. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, et al. Treatment of psoriatic arthritis with anti-tumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
4. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001;26:27-9.
5. Müller W, Herrmann B. Cyclosporin A for psoriasis [letter]. N Engl J Med 1979;301:555.
6. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
7. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
8. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991;138: 129-40.
9. Terajima S, Higaki M, Igarashi Y, Nogita T, Kawashima M. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 1998;290: 246-52.
10. O'Dougherty U, Inaba M, Deguchi N, Hagi K, Yasumizu R, Ikehara S, et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte conditioned medium. J Exp Med 1993;178:1067-78.
11. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
12. Schopf RE, Höcher J, Rehder M, Farber L, Morsches B. Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis. Arch Dermatol Res 1992;284:227-31.
13. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357: 1842-7.
14. Kragballe K, Beck HI, Sogard H. Improvement of psoriasis by topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988;119:223-30.
15. Schopf RE, Hoffmann A, Jung M, Morsches B, Bork K. Stimulation of T cells by autologous mononuclear leukocytes and epidermal cells in psoriasis. Arch Dermatol Res 1986;279:89-94.
16. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991;24:675-85.
17. Dobmeyer JM, Dobmeyer TS, Schopf RE. Importance of HLA-DR+ and CD1a+ epidermal cells for cytokine production in psoriasis. Adv Exp Med Biol 1995;378:539-41.
18. Oppenheim JJ, Ruscetti FW. Cytokines. In: Stites DP, Terr AI, Parslow TG, editors. Medical immunology. 9th ed. Stamford (CT): PrenticeHall International, Appleton & Lange; 1999, p. 149-68.
19. Schopf RE, Keller R, Rehder M, Benes P, Kallinowski F, Vaupel P. TNF alpha primes polymorphonuclear leukocytes for an enhanced respiratory burst to a similar extent as bacterial lipopolysaccharide. J Invest Dermatol 1990;95(Suppl 6):216S-218S.
20. Kapp A, Komann A, Schopf E. Effect of tumor necrosis factor alpha in vivo on human granulocyte oxidative metabolism. Arch Dermatol Res 1991;283:362-5.
21. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-5.
22. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.